Skip to main content
SpringerLink
Log in

The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Cyclooxygenase (COX), which have the isoforms of COX-1 and COX-2, is the key enzyme of prostaglandins biosynthesis. Especially, COX-2 is induced in inflammatory disease such as Diabetes Mellitus (DM). Resveratrol (RSV), a natural antioxidant, has a beneficial role in prevention of inflammatory disease. We investigated the changes of COX-1 and COX-2 mRNA expression and protein level in diabetic rat kidney after RSV treatment. Three months-old, 44 Wistar albino male rats, which were divided into six groups such as control group, sodium citrate buffer (sham control) group, diabetic group (DM), Dimethyl Sulfoxide induced control group, RSV treated sham control group (RSV) and RSV treated diabetic group (DM + RSV) were used for the study. Experimental diabetes was induced by intraperitoneal injection of 55 mg/kg Streptozotocin. After the induction of chronic diabetes 10 mg/kg per day RSV was administered intraperitoneally for 4 weeks. In this study. RSV has no significant effect on COX-1 mRNA expression in diabetic rat kidney (P > 0.05). Immunohistochemical study showed that COX-1 expression was slightly inhibited in RSV group and was not significantly supressed in DM + RSV group. When comparing control and treated groups, there were no significant differences in COX-2 mRNA or protein levels (P > 0.05). In conclusion, our results indicate that resveratrol do not significantly affect COX gene and protein expression. Therefore, different therapy strategies such as combination with other antidiabetic drugs may tried in STZ induced animal model for reducing diabetic symptoms and altering COX-1 and COX-2 mRNA or protein levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 38:97–120. doi:10.1146/annurev.pharmtox.38.1.97

    Article  CAS  PubMed  Google Scholar 

  2. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 69:145–182. doi:10.1146/annurev.biochem.69.1.145

    Article  CAS  PubMed  Google Scholar 

  3. Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271:33157–33160

    Article  CAS  PubMed  Google Scholar 

  4. Dubois RN, Abramson SB, Crofford L et al (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063–1073

    CAS  PubMed  Google Scholar 

  5. The Expert Committe on the diagnosis, classification of DM (2004) Report of the expert committe on the diagnosis and classification of DM. Diabetes Care 27:5–10

    Article  Google Scholar 

  6. Atkinson MA, Maclaren NK (1994) The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331:1428–1436

    Article  CAS  PubMed  Google Scholar 

  7. Robertson RP, Harmon JS (2006) Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 41:177–184. doi:10.1016/j.freeradbiomed.2005.04.030

    Article  CAS  PubMed  Google Scholar 

  8. Martinez J, Moreno JJ (2000) Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 59:865–870. doi:10.1016/S0006-2952(99)00380-9

    Article  CAS  PubMed  Google Scholar 

  9. Szewczuk LM, Forti L, Stivala LA, Penning TM (2004) Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2. J Biol Chem 279:22727–22737. doi:10.1021/np0498410

    Article  CAS  PubMed  Google Scholar 

  10. Fremont L (2000) Biological effects of resveratrol. Life Sci 66:663–673. doi:10.1016/S0024-3205(99)00410-5

    Article  CAS  PubMed  Google Scholar 

  11. Frankel EN, Waterhouse AL, Kinsella JE (1993) Inhibition of human LDL oxidation by resveratrol. Lancet 341:1103–1104. doi:10.1016/0140-6736(93)92472-6

    Article  CAS  PubMed  Google Scholar 

  12. Belguendouz L, Fremont L, Gozzelino MT (1998) Interaction of trans-resveratrol with plasma lipoproteins. Biochem Pharmacol 55:811–816. doi:10.1016/S0006-2952(97)00544-3

    Article  CAS  PubMed  Google Scholar 

  13. Pace-Asciak CR, Hahn S, Diamandis EP et al (1995) The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235:207–219. doi:10.1016/0009-8981(95)06045-1

    Article  CAS  PubMed  Google Scholar 

  14. Jang M, Cai L, Udeani GO, Slowing KV et al (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220. doi:10.1126/science.275.5297.218

    Article  CAS  PubMed  Google Scholar 

  15. Cui J, Juhasz B, Tosaki A et al (2002) Cardioprotection with grapes. J Cardiovasc Pharmocol 40:762–769

    Article  CAS  Google Scholar 

  16. Pervaiz S (2003) Resveratrol: from grapevines to mammalian biology. FASEB J 17:1975–1985. doi:10.1096/fj.03-0168rev

    Article  CAS  PubMed  Google Scholar 

  17. Banerjee S, Bueso-Ramos C, Aggarwal BB (2002) Suppression of 7, 12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62:4945–4954

    CAS  PubMed  Google Scholar 

  18. Gusman J, Malonne H, Atassi G (2001) A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22:1111–1117

    Article  CAS  PubMed  Google Scholar 

  19. Subbaramaiah K, Chung WJ, Michaluart P et al (1998) Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273:21875–21882

    Article  CAS  PubMed  Google Scholar 

  20. Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K (2006) Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 76:69–75. doi:10.1159/000089720

    Article  CAS  PubMed  Google Scholar 

  21. Su HC, Hung LM, Chen JK (2006) Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 290:1339–1346. doi:10.1152/ajpendo.00487.2005

    Article  Google Scholar 

  22. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:36

    Article  Google Scholar 

  23. Yu C, Shin YG, Chow A et al (2002) Human, rat, and mouse metabolism of resveratrol. Pharm Res 19:1907–1914. doi:10.1023/A:1021414129280

    Article  CAS  PubMed  Google Scholar 

  24. Hebbar V, Shen G, Hu R et al (2005) Toxicogenomics of resveratrol in rat liver. Life Sci 76:2299–2314. doi:10.1016/j.lfs.2004.10.039

    Article  CAS  PubMed  Google Scholar 

  25. Crowell JA, Korytko PJ, Morrissey RL et al (2004) Resveratrol-associated renal toxicity. Toxicol Sci 82:614–619. doi:10.1093/toxsci/kfh263

    Article  CAS  PubMed  Google Scholar 

  26. Juan ME, Vinardell MP, Planas JM (2002) The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132:257–260

    CAS  PubMed  Google Scholar 

  27. Bertelli AA, Giovannini L, Stradi R et al (1998) Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res 24:51–55

    CAS  PubMed  Google Scholar 

  28. Andlauer W, Kolb J, Siebert K, Fürst P (2000) Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res 26:47–55

    CAS  PubMed  Google Scholar 

  29. Marchant K (2008) Diabetes and chronic kidney disease: a complex combination. Br J Nurs 17:356–361

    PubMed  Google Scholar 

  30. Fujisawa T, Ikegami H, Ogihara T (2006) Diabetic complications and their features in the elderly. Nippon Rinsho 64:112–116

    PubMed  Google Scholar 

  31. Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454. doi:10.2337/db08-0057

    Article  CAS  PubMed  Google Scholar 

  32. Tilg H, Moschen AR (2008) Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14:222–231. doi:10.2119/2007-00119

    Article  CAS  PubMed  Google Scholar 

  33. Kundu JK, Surh YJ (2004) Molecular basis of chemoprevention by resveratrol: NF-κB and AP-1 as potential targets. Mutat Res 555:65–80. doi:10.1016/j.mrfmmm.2004.05.019

    CAS  PubMed  Google Scholar 

  34. Wang JL, Cheng HF, Zhang MZ, McKanna JA, Harris RC (1998) Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 275:613–622

    Google Scholar 

  35. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S (2001) Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107(7):889–898

    Article  CAS  PubMed  Google Scholar 

  36. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94(6):2504–2510

    Article  CAS  PubMed  Google Scholar 

  37. Fang C, Jiang Z, Tomlinson DR (1997) Expression of constitutive cyclo-oxygenase (COX-1) in rats with streptozotocin-induced diabetes: effects of treatment with evening primrose oil or an aldose reductase inhibitor on COX-1 mRNA levels. Prostaglandins Leukot Essent Fatty Acids 56:157–163

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by Gazi University Research Fund as a project with code number 01/2007-34.

Author information

Authors and Affiliations

  1. Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, Besevler, 06500, Ankara, Turkey

    Atiye Seda Yar, Sevda Menevse & Ebru Alp

  2. Department of Histology and Embriology, Faculty of Medicine, Gazi University, Besevler, 06500, Ankara, Turkey

    Fatma Helvacioglu & Gulnur Take

Authors
  1. Atiye Seda Yar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sevda Menevse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ebru Alp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fatma Helvacioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gulnur Take
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atiye Seda Yar.

Additional information

Disclaimer: This study was presented in the form of a poster to III. International Congress of Molecular Medicine, held on 5–8 May 2009 in Turkey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yar, A.S., Menevse, S., Alp, E. et al. The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys. Mol Biol Rep 37, 2323–2331 (2010). https://doi.org/10.1007/s11033-009-9737-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-009-9737-6

Keywords

Search

Navigation